Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays

Journal of Cheminformatics

Volumn 6, Issue 1, 2014, Pages

  Krasowski, Matthew D ^a   Ekins, Sean ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Collaborations in Chemistry ^*  (United States)

Author keywords

Amphetamines; Cannabinoids; Molecular models; Similarity; Toxicology

Indexed keywords

EID: 84901401804     PISSN: None     EISSN: 17582946     Source Type: Journal    
DOI: 10.1186/1758-2946-6-22     Document Type: Article

References (78)

1. Position of immunological techniques in screening in clinical toxicology. George S, Clin Chem Lab Med 2004 42 1288 1309 15576291 (Pubitemid 39600331)
2. The utility of immunoassays for urine drug testing. Melanson SE, Clin Lab Med 2012 32 429 447 10.1016/j.cll.2012.06.004 22939301
3. Urine drug screening in the medical setting. Hammett-Stabler CA, Pesce AJ, Cannon DJ, Clin Chim Acta 2002 315 125 135 10.1016/S0009-8981(01)00714-8 11728415 (Pubitemid 33145253)
4. Urine drug screening: practical guide for clinicians. Moeller KE, Lee KC, Kissack JC, Mayo Clinic Proc 2008 83 66 76 10.4065/83.1.66
5. Advanced urine toxicology testing. Tenore PL, J Addict Dis 2010 29 436 448 10.1080/10550887.2010.509277 20924879
6. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL, Clin Toxicol (Phila) 2012 50 733 742 10.3109/15563650.2012.713108 22888997
7. Amphetamine designer drugs-an overview and epidemiology. Christophersen AS, Toxicol Lett 2000 112-113 127 131 (Pubitemid 30138113)
8. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Cottencin O, Rolland B, Karila L, Curr Pharm Des 2013 2013 2013 in press
9. Synthetic Cannabinoids: A New Frontier of Designer Drugs. Gunderson EW, Ann Intern Med 2013 159 563 564 24018791
10. Designer cathinones-an emerging class of novel recreational drugs. Zawilska JB, Wojcieszak J, Forensic Sci Int 2013 231 42 53 10.1016/j.forsciint. 2013.04.015 23890615
11. Legal highs-legal aspects and legislative solutions. Kapka-Skrzypczak L, Kulpa P, Sawicki K, Cyranka M, Wojtyla A, Kruszewski M, Ann Agric Environ Med 2011 18 304 309 22216803
12. Legal controls on cannabimimetics: An international dilemma? King LA, Drug Test Anal 2013 6 80 87 23881527
13. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order. United States Department of Justice, Fed Regist 2013 78 28735 28739 23678676
14. Congress agrees to add 26 synthetic drugs to Controlled Substances Act. http://www.justice.gov/dea/pubs/pressrel/pr061912.html
15. Analytical toxicology of emerging drugs of abuse. Peters FT, Martinez-Ramirez JA, Ther Drug Monit 2010 32 532 539 10.1097/FTD. 0b013e3181f33411 20814349
16. Shulgin A, Shulgin A, PIHKAL: A Chemical Love Story Berkeley, CA: Transform Press 1991
17. Shulgin A, Shulgin A, TIHKAL: The Continuation Berkeley, CA: Transform Press 1997
18. "Bath salts" intoxication. Ross EA, Watson M, Goldberger B, N Engl J Med 2011 365 967 968 10.1056/NEJMc1107097 21899474
19. Are "Bath Salts" the next generation of stimulant abuse? Winder GS, Stern N, Hosanagar A, J Subst Abuse Treat 2012 44 42 45 22445773
20. Design, synthesis and pharmacology of cannabimimetic indoles. Huffman JW, Dai D, Bioorg Med Chem 1994 4 563 566 10.1016/S0960-894X(01)80155-4 (Pubitemid 24131892)
21. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. Shanks KG, Dahn T, Terrell AR, J Anal Toxicol 2012 36 145 152 10.1093/jat/bks013 22417829
22. Spice drugs as a new trend: mode of action, identification and legislation. Vardakou I, Pistos C, Spiliopoulou C, Toxicol Lett 2010 197 157 162 10.1016/j.toxlet.2010.06.002 20566335
23. Modulating the endocannabinoid system in human health and disease-successes and failures. Pacher P, Kunos G, FEBS J 2013 280 1918 1943 10.1111/febs.12260 23551849
24. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Seely KA, Lapoint J, Moran JH, Fattore L, Prog Neuropsychopharmacol Biol Psychiatry 2012 39 234 243 10.1016/j.pnpbp.2012.04.017 22561602
25. The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Brents LK, Prather PL, Drug Metab Rev 2014 46 72 85 10.3109/03602532.2013. 839700 24063277
26. Multicomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-Experience from the Swedish population. Al-Saffar Y, Stephanson NN, Beck O, J Chromatogr B Analyt Technol Biomed Life Sci 2013 930 112 120 23727875
27. Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Bell C, George C, Kicman AT, Traynor A, Drug Test Anal 2011 3 496 504 10.1002/dta.306 21744513
28. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. Dresen S, Kneisel S, Weinmann W, Zimmermann R, Auwarter V, J Mass Spectrom 2011 46 163 171 10.1002/jms.1877 21259394
29. Scheduled multiple reaction monitoring algorithm as a way to analyse new designer drugs combined with synthetic cannabinoids in human serum with liquid chromatography-tandem mass spectrometry. Dziadosz M, Weller JP, Klintschar M, Teske J, J Chromatogr B Analyt Technol Biomed Life Sci 2013 929 84 89 23669607
30. Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. ElSohly MA, Gul W, Elsohly KM, Murphy TP, Madgula VL, Khan SI, J Anal Toxicol 2011 35 487 495 10.1093/anatox/35.7.487 21871158
31. Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. Hutter M, Kneisel S, Auwarter V, Neukamm MA, J Chromatogr B Analyt Technol Biomed Life Sci 2012 903 95 101 22835826
32. Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. Kacinko SL, Xu A, Homan JW, McMullin MM, Warrington DM, Logan BK, J Anal Toxicol 2011 35 386 393 10.1093/anatox/35.7.386 21871146
33. Detection and tentative identification of urinary phase I metabolites of phenylacetylindole cannabimimetics JWH-203 and JWH-251, by GC-MS and LC-MS/MS. Kavanagh P, Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V, J Chromatogr B Analyt Technol Biomed Life Sci 2013 934 102 108 23917406
34. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. Kneisel S, Auwarter V, J Mass Spectrom 2012 47 825 835 10.1002/jms.3020 22791249
35. Replacing immunoassays for mephedrone, ketamines and six amphetamine-type stimulants with flow injection analysis tandem mass spectrometry. Lua IA, Lin SL, Lin HR, Lua AC, J Anal Toxicol 2012 36 575 581 10.1093/jat/bks068 22933658
36. Quantitation of amphetamine-type stimulants by LC-MS/MS. Middleberg RA, Homan J, Methods Mol Biol 2012 902 105 114 10.1007/978-1-61779-934-1-9 22767111
37. Identification of Novel Third-Generation Synthetic Cannabinoids in Products by Ultra-Performance Liquid Chromatography and Time-of-Flight Mass Spectrometry. Shanks KG, Behonick GS, Dahn T, Terrell A, J Anal Toxicol 2013 37 517 525 10.1093/jat/bkt062 23946450
38. A high-sensitivity ultra-high performance liquid chromatography/high- resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Sundstrom M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanpera I, Anal Bioanal Chem 2013 405 8463 8474 10.1007/s00216-013-7272-8 23954996
39. Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. Swortwood MJ, Boland DM, DeCaprio AP, Anal Bioanal Chem 2013 405 1383 1397 10.1007/s00216-012-6548-8 23180084
40. First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry. Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA, Clin Chem 2013 59 1638 1648 10.1373/clinchem.2013.209965 24014837
41. Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamine and methamphetamine. Apollonio LG, Whittall IR, Pianca DJ, Kyd JM, Maher WA, J Anal Toxicol 2007 31 208 213 10.1093/jat/31.4.208 17555644 (Pubitemid 46708661)
42. Evaluation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamines. Kerrigan S, Mellon MB, Banuelos S, Arndt C, J Anal Toxicol 2011 35 444 451 10.1093/anatox/35.7.444 21871153
43. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View, and the Emit(R) assays for use in drug enforcement. Nakanishi K, Miki A, Zaitsu K, Kamata H, Shima N, Kamata T, Katagi M, Tatsuno M, Tsuchihashi H, Suzuki K, Forensic Sci Int 2012 217 174 181 10.1016/j.forsciint.2011.11.003 22154438
44. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays. Petrie M, Lynch KL, Ekins S, Chang JS, Goetz RJ, Wu AH, Krasowski MD, Clin Toxicol (Phila) 2013 51 83 91 10.3109/15563650.2013.768344 23387345
45. Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays. Swortwood MJ, Hearn WL, Decaprio AP, in press
46. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. Arntson A, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B, J Anal Toxicol 2013 37 284 290 10.1093/jat/bkt024 23625703
47. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. Krasowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S, BMC Emerg Med 2009 9 5 19400959
48. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Krasowski MD, Siam MG, Iyer M, Pizon AF, Giannoutsos S, Ekins S, Clin Chem 2009 55 1203 1213 10.1373/clinchem.2008.118638 19342505
49. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Krasowski MD, Siam MG, Iyer M, Ekins S, Ther Drug Monit 2009 31 337 344 10.1097/FTD.0b013e31819c1b83 19333148
50. Application of belief theory to similarity data fusion for use in analog searching and lead hopping. Muchmore SW, Debe DA, Metz JT, Brown SP, Martin YC, Hajduk PJ, J Chem Inf Model 2008 48 941 948 10.1021/ci7004498 18416545
51. Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, Jacoby E, Schuffenhauer A, J Chem Inform Comput Sci 2004 44 1177 1185 10.1021/ci034231b
52. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, Jacoby E, Schuffenhauer A, Org Biomol Chem 2004 2 3256 3266 10.1039/b409865j 15534703
53. Enhanced ranking of PknB Inhibitors using data fusion methods. Seal A, Yogeeswari P, Sriram D, Consortium O, Wild DJ, J Cheminform 2013 5 2 10.1186/1758-2946-5-2 23317154
54. Combination of similarity rankings using data fusion. Willett P, J Chem Inf Model 2013 53 1 10 10.1021/ci300547g 23297768
55. A CROC stronger than ROC: measuring, visualizing and optimizing early retrieval. Swamidass SJ, Azencott CA, Daily K, Baldi P, Bioinformatics 2010 26 1348 1356 10.1093/bioinformatics/btq140 20378557
56. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. Ewald AH, Peters FT, Weise M, Maurer HH, J Chromatogr B Analyt Technol Biomed Life Sci 2005 824 123 131 10.1016/j.jchromb.2005.07.007 16027051 (Pubitemid 41215589)
57. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, Katagi M, Tsuchihashi H, Xenobiotica 2006 36 709 723 10.1080/00498250600780191 16891251 (Pubitemid 44195985)
58. An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts" Lopez-Arnau R, Martinez-Clemente J, Carbo M, Pubill D, Escubedo E, Camarasa J, Prog Neuropsychopharmacol Biol Psychiatry 2013 45 64 72 23603357
59. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Maurer HH, Kraemer T, Springer D, Staack RF, Ther Drug Monit 2004 26 127 131 10.1097/00007691-200404000-00007 15228152 (Pubitemid 38501205)
60. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Meyer MR, Wilhelm J, Peters FT, Maurer HH, Anal Bioanal Chem 2010 397 1225 1233 10.1007/s00216-010-3636-5 20333362
61. Metabolism of designer drugs of abuse. Staack RF, Maurer HH, Curr Drug Metab 2005 6 259 274 10.2174/1389200054021825 15975043 (Pubitemid 40753856)
62. Determination of a newly encountered designer drug "p- methoxyethylamphetamine" and its metabolites in human urine and blood. Zaitsu K, Katagi M, Kamata T, Kamata H, Shima N, Tsuchihashi H, Hayashi T, Kuroki H, Matoba R, Forensic Sci Int 2008 177 77 84 10.1016/j.forsciint.2007.11. 001 18155375
63. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL, PLoS One 2011 6 21917 10.1371/journal.pone.0021917 21755008
64. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH, Anal Chem 2011 83 6381 6388 10.1021/ac201377m 21740038
65. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH, Drug Metab Dispos 2012 40 2174 2184 10.1124/dmd.112.047530 22904561
66. Monitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases. Jang M, Yang W, Choi H, Chang H, Lee S, Kim E, Chung H, Forensic Sci Int 2013 231 13 19 10.1016/j.forsciint.2013.03.053 23890611
67. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH, Anal Chem 2011 83 4228 4236 10.1021/ac2005636 21506519
68. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Sobolevsky T, Prasolov I, Rodchenkov G, Forensic Sci Int 2010 200 141 147 10.1016/j.forsciint.2010.04.003 20430547
69. Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Wohlfarth A, Scheidweiler KB, Chen X, Liu HF, Huestis MA, Anal Chem 2013 85 3730 3738 10.1021/ac3037365 23458260
70. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z, Biochem Pharmacol 1995 50 83 90 7605349
71. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R, Science 1992 258 1946 1949 10.1126/science.1470919 1470919 (Pubitemid 23026736)
72. Gomella LG, Haist S, Adams AG, Smith KM, Clinician's pocket drug reference 2008 New York: McGraw-Hill Companies 2008
73. Rapid identification of novel P-glycoprotein ligands. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S, Drug Metab Dispos 2006 34 1976 1984 10.1124/dmd.106.012351 16997908 (Pubitemid 44837758)
74. In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Ekins S, Johnston JS, Bahadduri P, D'Souza VM, Ray A, Chang C, Swaan PW, Pharmaceut Res 2005 22 512 517 10.1007/s11095-005-2505-y (Pubitemid 40603247)
75. Molecular similarity: a key technique in molecular informatics. Bender A, Glen RC, Org Biomol Chem 2004 2 3204 3218 10.1039/b409813g 15534697
76. In silico pharmacology for drug discovery: applications to targets and beyond. Ekins S, Mestres J, Testa B, Br J Pharmacol 2007 152 21 37 10.1038/sj.bjp.0707306 17549046 (Pubitemid 47339897)
77. Virtual screening in drug discovery-a computational perspective. Reddy AS, Pati SP, Kumar PP, Pradeep HN, Sastry GN, Curr Protein Pept Sci 2007 8 329 351 10.2174/138920307781369427 17696867 (Pubitemid 47317040)
78. ROC curves in clinical chemistry: uses, misuses, and possible solutions. Obuchowski NA, Lieber ML, Wians FH Jr, Clin Chem 2004 50 1118 1125 10.1373/clinchem.2004.031823 15142978 (Pubitemid 38824221)